Novartis AG temporarily paused eight clinical trials of its experimental CAR-T therapy, rapcabtagene autoleucel, in late August 2026 after three patients died from severe immune responses. The trials were evaluating the CD19-directed treatment for autoimmune and neurological disorders. Novartis is reviewing the safety events alongside independent boards and regulators, while Bristol Myers Squibb has also paused similar trials as a precaution.
Novartis CAR-T trial suspension
- ▪Novartis AG is sharing information regarding the clinical trial safety events and patient deaths with regulatory authorities
- ▪Bristol Myers Squibb paused clinical trials of its own CAR-T treatment for autoimmune disorders as a precautionary measure
- ▪Novartis AG stopped enrolling and treating new patients in the rapcabtagene autoleucel trials while conducting a safety review of the observed events
- ▪The paused Novartis AG clinical trials were evaluating the experimental cell therapy for the treatment of autoimmune and neurological disorders
- ▪Novartis AG is working with independent safety boards overseeing each of the paused clinical trials
- ▪Novartis AG temporarily paused eight clinical trials of its experimental CAR-T therapy, rapcabtagene autoleucel (also known as rap-cel or YTB323), in late August 2026
Patient deaths from immune response
- ▪Three patients died in the Novartis AG clinical trials after experiencing a severe, dangerous immune system response
- ▪Novartis AG described the fatal severe immune response observed in the trials as a known safety risk associated with CAR-T therapies
CAR-T therapy mechanism
- ▪Chimeric antigen receptor T-cell (CAR-T) therapies modify a patient's own immune cells to recognize a specific target and destroy cancer cells
- ▪The experimental Novartis AG CAR-T treatment, rapcabtagene autoleucel, is a CD19-directed therapy
Story comments
Loading comments…